Entries / symptom
Vasomotor symptoms
moderate Evidence strength · Status: published · Source agreement: medium
Not medical advice
Menowise aggregates and organizes what the published literature reports, with citations. It does not diagnose, advise, or recommend treatment. Talk to a qualified clinician about your own care.
What the literature reports
Vasomotor symptoms — hot flushes and night sweats — are among the most common menopausal symptoms. The Menopause Society's 2023 Nonhormone Therapy Position Statement reports Level I evidence (good and consistent scientific evidence) supporting cognitive-behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin, and fezolinetant (a neurokinin 3 receptor antagonist); oxybutynin is graded at Levels I–II, and weight loss and stellate ganglion block at Levels II–III. The same statement reports that paced respiration, over-the-counter supplements and herbal remedies, cooling techniques, trigger avoidance, exercise, yoga, mindfulness-based intervention, relaxation, and acupuncture are not recommended for vasomotor symptoms. Hormone therapy is reported separately as the most effective treatment. This entry summarizes what the literature reports for navigation and is not medical advice.
Citations
-
The Menopause Society — 2023 Nonhormone Therapy Position Statement (Menopause, 2023; PMID 37252752) — The Menopause Society (Menopause journal) (2023)
Grades non-hormone therapies for VMS by evidence level (Level I = good and consistent scientific evidence).
Notes
Maps to entities.yml `vasomotor-symptoms` (symptom). Both signals derive from a single source (The Menopause Society 2023 Nonhormone Therapy Position Statement), so confidence is medium. evidence_strength set to moderate: the source is a professional-society position statement (a guideline) but it grades several therapies at Level I (controlled-trial) evidence; the underlying trials/meta-analyses are not directly cited here. The "not recommended" therapies are retained as negative evidence, not dropped (GD-0004). Cross-references: hormone therapy (`menopausal-hormone-therapy`) and fezolinetant (`fezolinetant`) are kept as distinct intervention entries per profile (drug/intervention vs. the symptom it is studied for).
Provenance
This entry is resolved from per-source signals; the raw claims are the audit trail behind it.
- Machine record: /data/sites/vasomotor-symptoms.yml (schema-valid, verbatim)
- Signals:
sig-20260710-vms-nonhormone-recommended,sig-20260710-vms-nonhormone-not-recommended - First recorded 2026-07-10 · last updated 2026-07-10